EXHIT ENTRE Comparative Effectiveness Trial

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 21% of the time (131 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-08-27. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Collaborators: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 59.2% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Phase: 2/3 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 24.5% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 14613 (raises risk) · Drug's FDA history
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: priorto randomizationpatientsopioidcompleted
  Phrases that lowered it: participantaminotransferasemoderatehospitalizedhospital
• Disease area, neurology: No (lowers risk) · Disease area
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) NCT06023459 · started 2024 · scored riskier than 27% of active trials completed
• Extended-release Pharmacotherapy for Opioid Use Disorder NCT05164549 · started 2019 · scored riskier than 17% of active trials completed
• Emergency Department-Initiated Buprenorphine Validation Network Trial NCT04225598 · started 2020 · scored riskier than 45% of active trials completed
• A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders NCT03232346 · started 2017 · scored riskier than 7% of active trials completed
• Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone NCT02294253 · started 2014 · scored riskier than 9% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.